α1-Antitrypsin deficiency and the risk of COVID-19: an urgent call to action

Article highlights emerging evidence indicates alpha1-proteinase inhibitor might inhibit infection by severe SARS-CoV-2, and that there is an urgent need to address the possibility that patients with α1-antitrypsin deficiency might be at increased risk of severe COVID-19.

Source:

The Lancet Respiratory Medicine